2-Deoxy-2-[ 18 F]fluoro- d -glucose PET/computed tomography ([ 18 F]FDG PET/CT) has proven to be a sensitive method for the detection and evaluation of hematologic malignancies, especially lymphoma. The increasing incidence and mortality rates of leukemia have raised significant concerns. Through the utilization of whole-body imaging, [ 18 F]FDG PET/CT provides a thorough assessment of the entire bone marrow, complementing the limited insights provided by biopsy samples. In this regard, [ 18 F]FDG PET/CT has the ability to assess diverse types of leukemia The utilization of [ 18 F]FDG PET/CT has been found to be effective in evaluating leukemia spread beyond the bone marrow, tracking disease relapse, identifying Richter's transformation, and assessing the inflammatory activity associated with acute graft versus host disease. However, its role in various clinical scenarios in leukemia remains unacknowledged. Despite their less common use, some novel PET/CT radiotracers are being researched for potential use in specific scenarios in leukemia patients. Therefore, the objectives of this review are to provide a thorough assessment of the current applications of [ 18 F]FDG PET/CT in the staging and monitoring of leukemia patients, as well as the potential for an expanding role of PET/CT in leukemia patients.
Keyphrases
- pet ct
- bone marrow
- positron emission tomography
- acute myeloid leukemia
- end stage renal disease
- computed tomography
- newly diagnosed
- ejection fraction
- chronic kidney disease
- peritoneal dialysis
- mesenchymal stem cells
- prognostic factors
- cardiovascular disease
- climate change
- lymph node
- patient reported outcomes
- risk factors
- metabolic syndrome
- cardiovascular events
- magnetic resonance
- coronary artery disease
- hepatitis b virus
- adipose tissue
- free survival
- mechanical ventilation
- respiratory failure
- insulin resistance